Intellia Therapeutics 주식 (NASDAQ: NTLA)

에 대한 최신 뉴스 Intellia Therapeutics (NASDAQ:NTLA) 주식

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Equities

News

Markets

CPRI

MNPR

NTLA

TSLA

미국 주식 시장은 목요일에 혼조세를 보였다. 나스닥 종합지수는 130포인트 이상 상승한 반면, 다우존스 지수는 0.3% 하락하여 42,374.36으로 마감되었다. S&amp;P 500 지수도 0.2% 상승하여 5,809.86으로 마감했다.

목요일 주목받은 주식: 모노파 테라퓨틱스, 인텔리아 테라퓨틱스, 카프리, 웨스턴 디지털 및 테슬라

ETFs

ACHR

ARKK

AVAV

BLDE

TDOC

VERV

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:TSLA)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

ARKW

COIN

ROKU

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:ROKU)와 코인베이스 글로벌(NASDAQ:COIN)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래

아크 인베스트는 로쿠 $730만의 주식을 매수, 비트코인 하락에 코인베이스 주식을 매각

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

WIIM

ZCAR

Zoomcar Holding shares are trading higher after the company reported a major expansion of its customer support team.

Prediction markets like Polymarket and Kalshi have <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41635149/2024-election-odds-on-polymarket-kalshi-show-trump-will-win-why-they-might-be-wrong">surged in popularity</a> during the <a href="https://www.benzinga.com/topic/2024-election">2024 election cycle</a>. Here&#8217;s all you need to know about the betting markets on Election Day as the U.S. elects a new president, either Donald Trump or Kamala Harris.
A Preface: Bettors on Polymarket, Kalshi, and other websites can continue betting even after the polls close. This is different than, say, sports betting where bets are locked after the game starts.
The betting odds will constantly update as votes are counted—favorable partial results for Trump will shift the odds in his column positively, and vice versa. As the race nears being called, the odds will converge on the winner.
The U.S. election could be called on Election Day—or it could take several weeks if a close tally requires recounts. Bettors can bet on the race at any time until the outcome is resolved.
Polymarket Policy: Polymarket <a href="https://polymarket.com/event/presidential-election-winner-2024?tid=1730829736678">lays</a> out its procedure for determining the outcome of its presidential market.
&#8220;This Presidential market resolves when the Associated Press, Fox, and NBC all call the election for the same candidate. In the unlikely event that doesn't happen, the market will remain open until inauguration and resolve to whoever gets inaugurated,&#8221; the website reads.
Kalshi Policy: Kalshi&#8217;s market is <a href="https://kalshi.com/markets/pres/presidential-elections">resolved</a> when the candidate is inaugurated.
&#8220;This market resolves when a candidate (or another representative of their party) is inaugurated as President for the term beginning January 20, 2025,&#8221; its rules read. &#8220;You can cash out of your position at any point in time.&#8221;
Why it Matters: Election night may present challenges such as confusion and misinformation. Bettors are encouraged to familiarize themselves with market rules before placing bets.
Several <a href="https://www.benzinga.com/news/24/11/41698607/kamala-harris-ready-if-trump-decides-to-falsely-declare-victory-we-are-prepared-to-respond">corroborating sources indicate</a> that Trump will prematurely declare victory on election night before all votes are counted. The Trump campaign <a href="https://www.benzinga.com/news/20/11/18202190/trump-declares-victory-ahead-of-results-from-key-states">acted similarly in 2020</a> in its loss to Joe Biden. Bettors should understand that while early results could indicate the direction of the race, it will ultimately not be resolved until the requirements of Polymarket and Kalshi are met.
According to reports, Kamala Harris's campaign and Democratic Party officials anticipate a <a href="https://www.benzinga.com/news/24/11/41698607/kamala-harris-ready-if-trump-decides-to-falsely-declare-victory-we-are-prepared-to-respond">premature victory declaration</a> by Trump in the 2024 election and are reportedly preparing a swift response. The Trump campaign <a href="https://www.benzinga.com/news/20/11/18202190/trump-declares-victory-ahead-of-results-from-key-states">took a similar approach</a> in 2020 during its loss to Joe Biden.
Bettors should be aware that while early results may indicate the potential direction of the race, the final outcome will not be determined until the conditions set by Polymarket and Kalshi are fulfilled.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41748843/trump-holds-edge-in-betting-markets-on-election-day-while-experts-call-tight-race-for-harris">Trump Holds Edge In Betting Markets On Election Day, While Experts Call Tight Race For Harris</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Politics

How Late Can You Bet On The US Election Through Polymarket, Kalshi? Everything You Need To Know

Trading Ideas

Hawaiian Electric Shares Halted Pending News

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 gaining around 1% on Tuesday.
The Dow traded up 0.96% to 42,197.88 while the NASDAQ rose 1.26% to 18,408.47. The S&amp;P 500 also rose, gaining, 1.03% to 5,771.80.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41741538/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Consumer discretionary shares surged by 1.8% on Tuesday.
In trading on Tuesday, energy shares rose by just 0.3%.
Top Headline
Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) posted downbeat results for its third quarter
The company reported third-quarter adjusted earnings per share of $1.37 missing the street view of $1.41. Yum! Brands reported a 4% increase in same-store sales for Taco Bell in the U.S., and a 9% unit growth for KFC International. The company's quarterly revenues of $1.826 billion missed the analyst consensus of $1.899 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares shot up 170% to $0.5189 after the company announced it secured an AUS$1 million milestone payment from Carina Biotech for its BNC101 oncology program, with the potential to earn up to AUS$118 million.</li>
<li>Shares of Vimeo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) got a boost, surging 44% to $6.91 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter sales guidance above estimates.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares were also up, gaining 33% to $2.43 after the company highlighted data showing the potential of inflammasome inhibition to protect pancreatic islet beta cells and attenuate progression from obesity to insulin resistance and type 2 diabetes.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) shares dropped 40% to $3.55 after the company reported worse-than-expected Q3 sales results. Also, multiple firms downgraded their respective ratings on the company and lowered their respective price targets.</li>
<li>Shares of Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) were down 41% to $0.8499 following downbeat quarterly results.</li>
<li>Bioventus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) was down, falling 18% to $11.19 after the company announced third-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 0.3% to $71.70 while gold traded up 0.2% at $2,750.20.
Silver traded up 0.4% to $32.725 on Tuesday, while copper rose 0.7% to $4.4645.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 rose 0.06%, Germany's DAX gained 0.57% and France's CAC 40 rose 0.48%. Spain's IBEX 35 Index rose 0.29%, while London's FTSE 100 fell 0.14%.
Spain's consumer confidence indicator declined by 4.6 points to a reading of 84.8 in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 1.11%, Hong Kong's Hang Seng Index gaining 2.14%, China's Shanghai Composite Index gaining 2.32% and India's BSE Sensex gaining 0.88%.
Economics
<ul>
<li>The trade deficit in the U.S. increased to $84.4 billion in September, recording the highest level since April 2022, and above market estimates of a $84.1 billion gap, versus a revised $70.8 billion gap in August.</li>
<li>The ISM services PMI rose to 56 in October, recording the highest reading since Aug. 2022. </li>
<li>The S&amp;P Global composite PMI rose to 54.1 in October compared to 54.0 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41743859/top-3-consumer-stocks-that-may-keep-you-up-at-night-this-quarter">Top 3 Consumer Stocks That May Keep You Up At Night This Quarter</a></li>
</ul>

Earnings

Eurozone

Commodities

BNOX

VMEO

VRCA

ZVSA

Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings

This year&#8217;s <a href="https://www.benzinga.com/markets/esg/24/05/39012013/noaa-meteorologists-predict-aggressive-hurricane-season-what-it-means-for-home-depot-generac-other-s">hurricane season </a>is a deadly one for the eastern and Gulf Coast of the U.S. Several companies and ETFs could be affected by another tropical storm nearing the Gulf Coast.
The Storm: Tropical Storm Rafael, the 17th named storm of the 2024 season, formed in the Caribbean, <a href="https://www.nbcnews.com/weather/hurricanes/tropical-storm-rafael-forms-expected-hurricane-rcna178632">according</a> to NBC.
The storm passed by Jamaica on Tuesday. It is expected to strengthen into a hurricane on Tuesday near the Cayman Islands and pass over Western Cuba. From there, it will likely weaken into a tropical storm before making landfall near New Orleans. The path may change drastically before impacting the U.S.
The heaviest rain of up to 10 inches is expected in Jamaica.
Market Impacts: With a projected path in the Gulf of Mexico, Rafael could disrupt offshore oil and gas production, which could impact companies operating there.
Potentially affected stocks include major energy companies like Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), and Occidental Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), and ETFs like SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) and Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Storms in the Gulf of Mexico can also disrupt refining operations, which could impact refiners such as Marathon Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) and Valero Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>).
Construction companies like Vulcan Materials Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) and Martin Marietta Materials Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) might benefit from increased demand for repairs and rebuilding.
Recent extreme weather activity is linked to climate change. Hurricanes, which will become even more frequent over time, may encourage homeowners to purchase home generators. Generac Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) is the largest producer of home generators in the U.S.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: &#8216;Bond Vigilantes Have Been Voting Early&#8217;</a></li>
</ul>
Photo: Tropical Storm Rafael, 11.5.2024. Courtesy NOAA/Public Domain

Sector ETFs

GNRC

Tropical Storm Rafael Could Make US Landfall: 11 Stocks, ETFs To Watch

SPPL

SIMPPLE Australia And Mode Technology To Showcase Advanced Robotic Cleaning Solutions And Software Platform At New Zealand Cleaning Expo On November 6-7

In the current market session, Lennox Intl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) stock price is at $601.00, after a 0.61% decrease. However, over the past month, the company's stock increased by 2.48%, and in the past year, by 58.07%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1730835070_0.png" alt="Past Year Chart" />

<h3>Lennox Intl P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 26.68 in the Building Products industry, Lennox Intl Inc. has a higher P/E ratio of 28.72. Shareholders might be inclined to think that Lennox Intl Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730835070_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Lennox Intl

AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) has outperformed the market over the past 15 years by 10.77% on an annualized basis producing an average annual return of 22.43%. Currently, AutoZone has a market capitalization of $51.50 billion. 
Buying $100 In AZO: If an investor had bought $100 of AZO stock 15 years ago, it would be worth $2,140.90 today based on a price of $3046.35 for AZO at the time of writing.
<h3>AutoZone's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730835035_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth $2,100 Today

ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) has outperformed the market over the past 10 years by 9.93% on an annualized basis producing an average annual return of 20.84%. Currently, ASML Holding has a market capitalization of $267.40 billion. 
Buying $100 In ASML: If an investor had bought $100 of ASML stock 10 years ago, it would be worth $666.33 today based on a price of $673.07 for ASML at the time of writing.
<h3>ASML Holding's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730835030_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASML

Here's How Much $100 Invested In ASML Holding 10 Years Ago Would Be Worth Today

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) with a Buy and lowers the price target from $5.75 to $5.5.

Price Target

Analyst Ratings

GROY

HC Wainwright & Co. Maintains Buy on Gold Royalty, Lowers Price Target to $5.5

On Monday, Fidelity National Information Services, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41709529/fis-reports-strong-third-quarter-2024-results-and-raises-full-year-outlook" rel="noreferrer noopener">third-quarter revenue</a> of $2.57 billion, up 3% year over year, topping the analyst consensus of $2.56 billion. Adjusted&nbsp;EPS of $1.40 beat the analyst consensus of $1.29.
The company expects fiscal 2024 revenue of $10.14 billion &#8211; $10.17 billion (prior $10.12 billion &#8211; $10.17 billion) and adjusted EPS of $5.15 &#8211; $5.20 (prior $5.03 &#8211; $5.11).
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41745824/short-squeeze-globalfoundries-stock-soars-on-q3-earnings-beat-strong-q4-outlook" rel="noreferrer noopener">Short Squeeze &#8211; GlobalFoundries Stock Soars On Q3 Earnings Beat, Strong Q4 Outlook</a>
Multiple analysts rerated the stock after the print. RBC Capital analyst Daniel Perlin maintained Fidelity National Info with an Outperform and raised the <a href="https://www.benzinga.com/quote/FIS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $95 to $104</a>.
KeyBanc analyst Alex Markgraff remained Sector Weight on Fidelity National Info. Goldman Sachs analyst Will Nance reiterated a Buy on Fidelity National Info with a price target of $100, up from $97.
RBC Capital: Perlin highlighted FIS&#8217; recent performance, noting strength in core banking sales and operating leverage in capital markets. Banking segment adjusted revenue grew by 3% year-over-year to $1.71 billion, with an adjusted EBITDA margin of 45.2%, supported by cost-saving efforts and an increasing proportion of recurring revenue, up 6% year-over-year. The recent acquisition of Dragonfly, which offers liquidity management and fraud prevention for complex commercial clients, enhances FIS&#8217; digital offerings and opens cross-selling opportunities with banks not yet using FIS&#8217; core services.
The Capital Markets segment posted 7% adjusted revenue growth, reaching $730 million, with a 49.9% EBITDA margin. This was attributed to a favorable revenue mix and operational leverage. Management anticipates ongoing margin expansion in the segment, driven by increased recurring revenue and a boost in cross-selling activity across the enterprise, which rose 20% year-to-date.
KeyBanc: Markgraff observed that FIS reported better-than-expected third-quarter results and raised its full-year guidance. However, the increase was primarily due to reduced interest expenses and added Worldpay EMI contributions rather than core operational growth. Adjusted revenue in Banking grew 3% year-over-year, driven by steady recurring revenue. Capital Markets adjusted revenue also rose by 7%, reflecting substantial operating leverage and an advantageous revenue mix.
Despite an upbeat revenue beat, Markgraff noted that higher capital expenditures—partly from vendor pricing pressures—dampened immediate market response to the results. The outlook suggests strong momentum, particularly in Capital Markets, though Banking growth is expected to settle closer to the lower to midpoint of its projected range.
Goldman Sachs: Nance noted that FIS outperformed the S&amp;P with a 67 basis point rise, as investors seemed reassured by consistent performance and reaffirmed medium-term targets. Despite anticipated increases in third-party vendor costs impacting capital expenditures, management expressed confidence in maintaining cash flow in 2025. While Worldpay is no longer central to FIS&#8217; strategy, its EMI continues positively impacting EPS. Operationally, FIS saw strong execution with several key customer wins in the Asia-Pacific region, reinforcing confidence in its execution.
Looking ahead, Nance views FIS as a reliable, defensively positioned investment with moderate revenue growth and steady EPS growth, enhanced by capital returns and efficient margin management. He raised the price target, reflecting peer valuation adjustments driven by FIS&#8217; continued positive performance trajectory.
Price Action: FIS stock is down 3.21% at $86.82 at last check Tuesday.
Image: Shutterstock by PopTika
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41748807/thomson-reuters-q3-earnings-legal-corporate-segments-enjoy-revenue-boost-as-ceo-highlights-ai-inves" target="_blank" rel="noreferrer noopener">Thomson Reuters Q3 Earnings: Legal, Corporate Segments Enjoy Revenue Boost As CEO Highlights AI Investment</a></li>
</ul>

Analyst Color

Reiteration

Fidelity National Information Services' Banking, Capital Markets Growth Drive Optimism, Analysts Say

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) with a Hold.

Needham Reiterates Hold on Verrica Pharmaceuticals

Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) stock is trading lower on Tuesday. Bank of America expects the stock to experience some volatility after the company&#8217;s striking machinists voted to approve the plane maker&#8217;s <a href="https://www.benzinga.com/markets/equities/24/11/41736062/boeing-workers-end-seven-week-strike-by-accepting-new-contract-with-major-pay-increases">latest labor contract proposal</a>.
What To Know: The International Association of Machinists and Aerospace Workers (IAM) voted to ratify Boeing&#8217;s labor proposal on Monday, with 59% of the votes in favor of the deal.
In a new note to clients on Tuesday, BofA analyst Ronald Epstein said recently appointed Boeing CEO Kelly Ortberg &#8220;added another check to the &#8216;Boeing Turnaround&#8217; list&#8221; by bringing an end to what had been a 53-day strike. Although Epstein is optimistic about the news, he cautioned that a return to normal operations could still take a while. 
&#8220;While the strike ending and workers returning to the shopfloor is a meaningful step in the right direction, ramping back up will take time,&#8221; the BofA analyst said. 
Epstein pumped the brakes on Boeing&#8217;s production ramp, noting that some employees will have to go through retraining sessions after returning to work by Nov. 12.
The offer included a 38% wage increase over four years, enhanced retirement contributions and improved health benefits. Union members also gained flexibility in receiving their one-time $12,000 ratification bonus, with options to allocate it toward their paycheck, 401(k) or a combination of the two.
&#8220;While the full impact of the strike and how quickly production restarts remain to be determined we leave our estimates unchanged and maintain our Neutral rating. However, we do expect to see some volatility in Boeing&#8217;s share price,&#8221; the analyst said.
Related Link: <a href="https://www.benzinga.com/trading-ideas/technicals/24/11/41712908/palantir-q3-earnings-on-deck-as-cathie-wood-cuts-stake">Palantir Q3 Earnings On Deck As Cathie Wood Cuts Stake</a>
BA Price Action: At the time of writing, Boeing shares were down 2.05% at $151.94, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

Movers

Boeing Stock Is Trading Lower, Analyst Sees Volatility Ahead: What's Going On?

Wedbush analyst Nick Setyan reiterates Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Outperform and maintains $390 price target.

WING

Wedbush Reiterates Outperform on Wingstop, Maintains $390 Price Target

alab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) reported better-than-expected third-quarter <a href="https://www.benzinga.com/quote/ALAB/earnings">EPS and sales on Monday</a>.
Astera Labs reported quarterly earnings of 23 cents per share which beat the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $113.09 million which beat the analyst consensus estimate of $97.44 million.
&#8220;Astera Labs delivered strong Q3 results, setting our fifth consecutive quarterly revenue record and grew 47% versus the previous quarter,&#8221; said Jitendra Mohan, Astera Labs&#8217; Chief Executive Officer. &#8220;Our business has now entered a new growth phase with multiple product families ramping across AI platforms based upon both third-party GPUs and internally developed AI accelerators. With expanding product portfolio including the new Scorpio Fabric Switches, we are cementing our position as a critical part of AI connectivity infrastructure, delivering increased value to our hyperscaler customers, and unlocking additional multi-year growth trajectories for Astera.&#8221;
Astera Labs said it sees fourth-quarter revenue of $126 million to $130 million and adjusted earnings of 25 cents to 26 cents per share.
Astera Labs shares jumped 38.7% to trade at $96.60 on Tuesday.
These analysts made changes to their price targets on Astera Labs following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60a3a5a849aa07000157ebd9/tom-o'malley">Barclays analyst Tom O&#8217;Malley</a> maintained Astera Labs with an Overweight and raised the price target from $70 to $87.</li>
<li>Craig-Hallum analyst Richard Shannon maintained the stock with a Buy and raised the price target from $75 to $105.</li>
<li>Deutsche Bank analyst Ross Seymore maintained Astera Labs with a Buy and boosted the price target from $60 to $100.</li>
<li>J<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59f1c1bdefacff0001706787/harlan-sur">P Morgan analyst Harlan Sur</a> maintained the stock with an Overweight and raised the price target from $70 to $110.</li>
<li>Stifel analyst Tore Svanberg maintained Astera Labs with a Buy and boosted the price target from $80 to $100.</li>
<li>Morgan Stanley analyst Joseph Moore maintained Astera Labs with an Overweight and raised the price target from $74 to $94.</li>
<li>Roth MKM analyst Suji Desilva maintained the stock with a Buy and raised the price target from $80 to $105.</li>
</ul>
Considering buying ALAB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05134431/image-35-1024x573.png" alt="" class="wp-image-631048" style="width:692px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05134431/image-35-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05134431/image-35-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05134431/image-35-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05134431/image-35.png 1192w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41746021/this-ebay-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This eBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a></li>
</ul>

ALAB

These Analysts Boost Their Forecasts On Astera Labs After Upbeat Results

Kirby's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEX#NYSE">KEX</a>) short percent of float has risen 14.47% since its last report. The company recently reported that it has 928 thousand shares sold short, which is 1.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kirby Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730834122_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kirby has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kirby's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kirby's peer group average for short interest as a percentage of float is 3.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Kirby?

ZIM Integrated Shipping's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) short percent of float has risen 12.27% since its last report. The company recently reported that it has 17.67 million shares sold short, which is 18.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.48 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ZIM Integrated Shipping Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730834117_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ZIM Integrated Shipping has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ZIM Integrated Shipping's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ZIM Integrated Shipping's peer group average for short interest as a percentage of float is 2.44%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About ZIM Integrated Shipping?

Bright Horizons Family's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) short percent of float has risen 21.52% since its last report. The company recently reported that it has 492 thousand shares sold short, which is 0.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Bright Horizons Family Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730834111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bright Horizons Family has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bright Horizons Family's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Bright Horizons Family's peer group average for short interest as a percentage of float is 5.72%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BFAM

Peering Into Bright Horizons Family's Recent Short Interest

Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) shares are trading lower on Tuesday following weak third-quarter <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41730393/cleveland-cliffs-q3-earnings-revenue-eps-miss-on-weaker-demand-and-pricing-shares-slide" rel="noreferrer noopener">results reported on Tuesday</a>.
The company reported third-quarter revenue of&nbsp;$4.57 billion, versus&nbsp;estimates&nbsp;of $4.77 billion, and adjusted loss per share of $0.33, versus estimates for a loss of $0.27.
Cleveland-Cliffs lowered its capital expenditures outlook for full year 2024 from a range of $650 million to $700 million to a new range of<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> $600 million to $650 million</a>.
In the earnings press release, the company said Stelco&#8217;s assets are well-capitalized, and it expects to benefit from the company&#8217;s cost advantages and strong business model on day one. Cleveland-Cliffs noted Stelco&#8217;s business has &#8220;virtually no exposure&#8221; to the automotive sector.&nbsp;
B Riley Securities analyst Lucas N. Pipes says that based on management&#8217;s earlier comments, they previously projected $985 million for 2025 and anticipate insights on the significant reductions.
The analyst adds that Cliffs&#8217; acquisition of Stelco was finalized on November 1, and they are eager to hear management&#8217;s thoughts on the integration process, potential synergies, debt reduction, and product mix.
Also, the analyst anticipates updated insights from management regarding the timeline for the integration process of the Stelco acquisition and the complete realization of the <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39770873/cleveland-cliffs-doubles-down-on-steel-with-2-5b-acquisition-expects-120m-in-annual-savings" rel="noreferrer noopener">$120 million in cost synergies</a>.
The analyst maintains the <a href="https://www.benzinga.com/quote/CLF/analyst-ratings">Buy rating and $21 price forecast.</a>
KeyBanc Capital Markets analyst Philip Gibbs writes that Cleveland-Cliffs reported EBITDA of $124 million for the quarter, compared to their estimate of $134 million. The slight shortfall in steel volumes appears to be linked to adjustments in automotive production and inventory.
Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Metals &amp; Mining ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XME#NYSE">XME</a>) and&nbsp;VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>).
Price Action: CLF shares are down 10.3% at $11.76 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/esg/24/11/41722922/trump-vs-harris-evgo-cleveland-cliffs-plug-power-nucor-brace-for-2024-election-impact" target="_blank" rel="noreferrer noopener">Trump Vs. Harris: EVgo, Cleveland-Cliffs, Plug Power, Nucor Brace For 2024 Election Impact</a></li>
</ul>

Cleveland-Cliffs' Q3 Shortfall Linked To Automotive Adjustments; Analysts Await Stelco Integration Insights

Guggenheim analyst Michael Morris maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Buy and raises the price target from $45 to $50.

FOXA

Guggenheim Maintains Buy on Fox, Raises Price Target to $50

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating today. Mani Foroohar has given his Bu...

Intellia Therapeutics: Promising Phase 2 Results and Growth Potential Justify Buy Rating

Citi analyst David Lebowitz lowered the firm's price target on Intellia Therapeutics (NTLA) to $19 from $25 and keeps a Neutral rating on the share...

Intellia Therapeutics price target lowered to $19 from $25 at Citi

David Lebowitz, an analyst from Citi, maintained the Hold rating on Intellia Therapeutics (NTLA – Research Report). The associated price target is ...

Intellia Therapeutics' NTLA-2002: Hold Rating Amid Competitive Challenges and Safety Concerns

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

Intellia Therapeutics ( ($NTLA) ) has provided an announcement. Intellia Therapeutics has announced promising Phase 2 results for NTLA-2002, a CRIS...

Intellia Therapeutics Advances with Promising Phase 2 Results

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2024 Update

Warning: NTLA is at high risk of performing badly

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on October 25. Debanjana Chatterje...

Intellia Therapeutics: Positive Outlook and Buy Rating Amid Promising Data for ATTR-CM Treatment

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

ALNY

ARKB

ARKF

ARKG

ARKQ

ARKX

BCRX

BEAM

CRSP

DKNG

HOOD

IONS

PATH

PLTR

RBLX

REGN

RXRX

SHOP

TKPHF

Press Releases

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

Health Care

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Ardelyx

Bicara Therapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Galapagos NV - American Depositary Shares

Galapagos

Gyre Therapeutics

Immunocore Holdings plc - American Depositary Shares

Immunocore Hldgs

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kura Oncology

Myriad Genetics

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma

Nurix Therapeutics

Novavax

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Upstream Bio

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Citigroup

Goldman Sachs

Baird

Chardan Capital

RBC Capital

미국 주식 시장은 목요일에 혼조세를 보였다. 나스닥 종합지수는 130포인트 이상 상승한 반면, 다우존스 지수는 0.3% 하락하여 42,374.36으로 마감되었다. S&amp;P 500 지수도 0.2% 상승하여 5,809.86으로 마감했다.
이날 소매 거래자와 투자자들의 주목을 받은 주요 주식은 다음과 같다:
모노파 테라퓨틱스 (MNPR)
모노파 테라퓨틱스의 주식은 605.40% 급등하여 $32.66에 마감하였으며, 장중 최고가는 $38.5, 최저가는 $4.87였다. 이 회사의 52주 최고가와 최저가는 각각 $38.5와 $1.37이다. 이 회사의 주가는 아스트라제네카(AstraZeneca Plc)의 알렉시온(Alexion)과의 윌슨병 치료제 ALXN-1840에 대한 <a href="https://www.benzinga.com/general/biotech/24/10/41525741/monopar-therapeutics-stock-jumps-4x-inks-licensing-pact-with-astrazeneca-for-once-terminated-phas">독점 전세계 라이선스 계약</a>에 합의한 후 급등했다.
인텔리아 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)
인텔리아 테라퓨틱스의 주가는 20.51% 하락하여 $15.85로 마감했다. 장중 최고가는 $17.74, 최저가는 $15.35였다. 이 회사의 52주 최고가와 최저가는 각각 $34.87와 $15.35이다. 주가는 <a href="https://www.benzinga.com/general/biotech/24/10/41524915/why-is-gene-therapy-focused-intellia-therapeutics-stock-trading-lower-on-thursday">유전자 치료제 NTLA-2002의 2단계 데이터 발표</a> 이후 하락했다.
참고: <a href="https://www.benzinga.com/markets/equities/24/10/41507504/elon-musk-shuts-down-traditional-tesla-25k-ev-rumors-calls-it-pointless-as-company-focuses-on-al?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">일론 머스크, 전통적인 테슬라 2만 5천 달러 EV 루머를 &#8216;무의미하다&#8217;고 일축하며 자율주행 미래에 집중한다고 밝혀</a>
카프리 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>)
카프리 홀딩스의 주가는 0.50% 하락하여 $41.60에 마감했다. 장중 최고가는 $42.21, 최저가는 $41.46였다. 이 회사의 52주 최고가와 최저가는 각각 $51.73와 $29.28이다. 주가는 태피스트리(Tapestry Inc.)와의 합병이 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%B9%B4%ED%94%84%EB%A6%AC%EC%9D%98-%EC%A3%BC%EC%8B%9D%EC%9D%80-%ED%85%8C%ED%94%BC%EC%8A%A4%ED%8A%B8%EB%A6%AC%EC%99%80%EC%9D%98-%ED%95%A9%EB%B3%91%EC%9D%B4-%EC%B0%A8%EB%8B%A8%EB%90%98%EC%9E%90-45/" target="_blank" rel="noopener">법원에 의해 차단되었다는 보도</a> 이후 급락했다.
웨스턴 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)
웨스턴 디지털의 주가는 0.44% 하락하여 $66.32로 마감했다. 장중 최고가는 $67.54, 최저가는 $66.20였다. 52주 최고가와 최저가는 각각 $81.55와 $35.62이다. 이 회사는 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9B%A8%EC%8A%A4%ED%84%B4-%EB%94%94%EC%A7%80%ED%84%B8%EC%9D%98-%EC%A3%BC%EA%B0%80%EB%8A%94-1%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81-%EB%B0%9C%ED%91%9C-%ED%9B%84-%EC%8B%9C%EA%B0%84%EC%99%B8-%EA%B1%B0/" target="_blank" rel="noopener">1분기 실적 발표</a>에서 분석가 예상치를 상회하는 시적을 발표한 후 주가가 상승했다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주가는 21.92% 상승하여 $260.48에 마감했다. 장중 최고가는 $262.12, 최저가는 $242.65였다. 52주 최고가와 최저가는 각각 $271와 $138.8이다. 주요 월가 애널리스트들이 <a href="https://www.benzinga.com/news/24/10/41515376/tesla-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-thursday">여러 회사에 대한 전망을 업데이트</a>했다. 베어드(Baird)는 서비스나우(ServiceNow)의 목표 주가를 올리고, 키뱅크(Keybanc)는 로켓 랩(Rocket Lab)의 목표 주가를 상향 조정했다. 한편, 파이퍼 샌들러(Piper Sandler)는 시높시스(Synopsys)의 목표 주가를 하향 조정하고, HC 웨인라이트는 DBV 테크놀로지스의 전망을 상향 조정했다. JP 모건은 넥스테라 에너지(NextEra Energy)를 상승 등급으로 조정하고, BMO 캐피털은 코스타 그룹(CoStar Group)의 목표 주가를 하향 조정했다.
이미지 출처: Shutterstock
벤징가와 함께 <a href="Premarket Movers &amp; News">상위 프리마켓 동향 및 뉴스</a>를 확인하시고 하루의 거래를 준비하세요.
다음 기사 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41490763/in-legal-weed-state-woman-faces-30-year-sentence-over-bong-water-aclu-steps-in?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">합법적인 대마초 주에서 한 여성이 대마초 물로 30년 형에 처해질 위기에 처하다: ACLU가 개입하다</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.
테슬라 주식
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 테슬라 지분을 줄여 13,213주를 매각했다. 이번 거래는 테슬라의 주가가 최근 화요일에 10.20% 급등해 4월 말 이후 최고의 장중 거래를 기록했다는 점을 감안하면 놀라운 일이었다. 특히 화요일에 아크 인베스트는 <a href="https://www.benzinga.com/markets/equities/24/07/39611275/cathie-woods-ark-invest-sells-tesla-shares-worth-14-5m-amid-rally-driven-by-q2-delivery-numbers-">1,450만 달러</a> 상당의 테슬라 주식을 매각했다.
이러한 상승은 주로 일론 머스크가 이끄는 이 회사의 <a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">2분기 실적</a>에 의해 주도되었다. 테슬라는 예상 차량 439,000대를 크게 초과하는 443,956대를 인도했다고 보고했다. 이러한 놀라운 상승세는 랠리를 촉진하여 주가를 2024년 최고치로 끌어올렸다. 판매의 대부분은 저렴한 모델 3 및 Y에서 이루어졌으며, 더 비싼 모델 X, S 및 신형 사이버트럭에서는 21,551대만 판매되었다.
최종 종가 246.39달러를 기준으로 수요일에 판매된 주식의 가치는 약 325만 달러에 달한다. 이날 테슬라 주가는 6.5% 급등했다.
기타 중요한 거래:
<ul>
<li>아크 인베스트의 ARKF 펀드는 텔레닥(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 팔았다.</li>
<li>ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 2,551주 매수하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 주를 팔았다.</li>
<li>ARKK 펀드는 아처 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>)의 주를 사고, 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주를 팔았다.</li>
<li>ARKQ 펀드는 에어로바이런먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)의 주를 팔았다. ARKX 펀드는 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)의 주를 샀다.</li>
</ul>
이미지는 셧터스톡을 통해 제공됨
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했다

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)와 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래
ARK 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 로쿠에서 127,540주를 매입했다. ARKK 펀드는 106,420주를 인수했고, ARKW 펀드는 21,120주를 추가했다. 이 거래액은 730만 달러에 달했다. 수요일, 로쿠의 주가는 정기 세션에서 4.6% 상승한 57.16달러로 마감했다.
특히 우드의 회사는 <a href="https://www.benzinga.com/markets/equities/24/06/39493817/cathie-wood-led-ark-invest-dumps-4-3m-worth-of-nvidia-shares-amid-rebound-swoops-into-buy-stock-">하루 전</a>에 530만 달러 상당의 로쿠 주식을 구매했다. 이러한 움직임은 <a href="https://www.benzinga.com/general/entertainment/24/06/39422115/roku-stocks-wild-ride-bullish-analysts-bet-on-growth-despite-competitive-threats" target="_blank" rel="noopener">치열한 강세와 약세 논쟁</a> 사이에 주식이 갇힌 로쿠의 격동적인 시장 움직임 속에서 이루어졌다.
TV 스트리밍 플랫폼이자 넷플릭스와 같은 스트리밍 플랫폼의 경쟁사인 로쿠는 <a href="https://www.benzinga.com/markets/equities/24/06/39295418/whats-going-on-with-tv-streaming-platform-rokus-shares-on-wednesday">최근</a> 광고 인벤토리와 광고주 수요를 직접 연결하는 광고 기술 솔루션인 로쿠 익스체인지(Roku Exchange)를 출시했다.
코인베이스 거래
아크 인베스트의 ARKW ETF는 703,393달러 상당의 코인베이스 주식 3,278주를 매각했다. 이번 판매는 미국 정부와 연결되어 있는 것으로 여겨지는 지갑을 통해 상당한 규모의 암호화폐가 코인베이스로 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39511595/uncle-sam-on-the-move-us-government-transfers-millions-in-bitcoin-to-coinbase" target="_blank" rel="noopener">이전</a>된 데 따른 것이다. 미국 정부는 2억 4,100만 달러 상당의 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ​​3,940개를 코인베이스로 이전했다.
미국 정부의 이러한 움직임으로 인해 암호화폐 시장이 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39516076/bitcoin-ethereum-dogecoin-retrace-on-fears-of-240m-sale-by-us-government-king-crypto-shoul">하락</a>했다. 비트코인은 이전 거래 세션에서 62,000달러로 약간 반등한 후 61,000달러 아래로 떨어졌다.
그 외 핵심 거래들:
<ul>
<li>아크 인베스트의 ARKG ETF는 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주식을 팔고 10X 지노믹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>)의 주식을 샀다.</li>
<li>ARKG 펀드는 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 매도하고 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 샀다.</li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>가 작성하고 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집한 바 있다.

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:
로빈후드에서 포지션을 축소하기로 한 아크 인베스트의 결정은 세 가지 ETF를 통해 실행되었다. ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 31,827주를 매각했고, ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 215,675주와 76,299주를 매각했다. 월요일 로빈후드의 종가 23.42달러를 기준으로 판매된 주식의 총 가치는 약 760만 달러이다.
로빈후드 주식의 변동성은 <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock" target="_blank" rel="noopener">밈 주식 열기가 부활</a>하는 가운데 발생했다. 최근 로빈후드의 CEO 블래디미어 테네브는 게임스탑에 투자한 것으로 유명한 로어링 키티(Roaring Kitty)이라고도 알려진 키스 길(Keith Gill)의 예정된 라이브 스트리밍으로 인한 트래픽 유입을 회사가 처리할 준비가 되었다고 발표했다. 이 회사는 또한 최근 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">10억 달러 규모의 자사주 매입</a>을 발표했는데, 이는 주가 상승 추세에 기여했다.
특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 등 주요 코인들이 적자로 거래되면서 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-" target="_blank" rel="noopener">고르지 못한 암호화폐 시장</a>을 배경으로 거래가 성사됐다.
다른 중요한 거래:
<ul>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): ARKG 및 ARKK를 통해 주식 매도.</li>
<li>아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): ARKG를 통해 주식 매입.</li>
<li>텔라닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG를 통해 주식 매도.</li>
<li>인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): ARKG 및 ARKK를 통해 주식 매입.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG 및 ARKK를 통해 주식 매도. 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): ARKG 및 ARKK를 통해 5,804주 매입.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CEO 일자리 대안에 대한 투자자의 협상</a>
이 이야기는 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>의 편집을 거쳐 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었습니다.

$ETH

ARCT

EXAS

VCYT

아크 인베스트가 게임스톱 관련 뉴스와 비트코인 변동성 속에서 로빈후드 주식 $7.6백만 매각

목요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)과 레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>)에서 상당한 거래를 성사시켰으며 두 회사 모두 눈에 띄는 움직임을 보였다.
아마존닷컴 거래:
아크 인베스트의 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 아마존 주식 53,368주를 매입했다. 이러한 움직임은 Amazon이 최근 760억 달러 규모의 11년 계약의 일환으로 NBA 미디어 권리를 <a href="https://www.benzinga.com/general/sports/24/06/39215473/amazon-makes-prime-bet-on-sports-with-nba-deal-streaming-platform-will-have-content-from-4-major-l">인수</a>한 이후에 나온 것이다. 이러한 전략적 움직임은 아마존 프라임 비디오(Amazon Prime Video) 스트리밍 플랫폼의 가입자 수를 늘릴 것으로 예상된다. 목요일 아마존의 종가 185달러를 기준으로 한 이번 거래 가치는 약 990만 달러이다.
레딧 거래:
별도의 거래에서, 아크 인베스트의 Ark 핀테크 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 레딧 주식 1,312주를 매입했다. 이번 매입은 레딧이 최근 고객 경험 관리 플랫폼 기업 스프링클(Sprinklr)과의 <a href="https://www.benzinga.com/news/24/06/39208968/whats-going-on-with-reddit-stock-today">확대된 파트너십 발표한</a> 것과 일치한다. 이 파트너십을 통해 스프링클 고객들은 레딧의 전체 광고 제품군에 액세스하고 레딧을 기업 광고 전략에 통합할 수 있다. 레딧의 목요일 종가 63.46달러를 기준으로 한 이 거래의 가치는 약 83,200달러이다.
다른 중요한 거래:
<ul>
<li>아크 인베스의 ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) 주식 25,736주를 매입하고, 이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)의 12,602주를 팔았다.</li>
<li>ARKK 펀드는 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>)의 106,192주를 매입하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 126,699주를 팔았다. ARKW 펀드는 서비스나우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)의 14,121주를 매도했다.</li>
</ul>
다른 중요한 거래를 읽어보세요: <a href="https://www.benzinga.com/markets/equities/24/06/39192292/amc-stock-rises-as-annual-shareholder-meeting-results-roll-in-whats-going-on?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AMC주가 상승, 연례 주주총회 결과 발표: 무슨 일이?</a>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 작성되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.

Comments

Intellia Therapeutics

뉴스

에 대한 최신 뉴스 Intellia Therapeutics (NASDAQ:NTLA) 주식

금요일, 10월 25, 2024

목요일, 7월 04, 2024

목요일, 6월 27, 2024

화요일, 6월 11, 2024

금요일, 6월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌